CareDx, Inc logo

CareDx, Inc

CDNA

NASDAQHealthcareMedical - Diagnostics & Research

Previous close

$48.61

+$1.62 · +3.45%

Aug 21, 4:00 PM ET

CDNA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

8

Overpriced

Momentum

70

Gaining

Sentiment

57

Mixed

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
John Walter Hanna Jr.
Listed since
Jul 17, 2014
Employees
763

Market position

Day range

Current $48.61

52-week range

Current $48.61

Open
$46.99
Previous close
$46.99
Volume
1.16M
1.19× average
Average volume
978.83K
Average daily volume
Market cap
2.51B USD
Beta
2.42
Market reference 1
50-day average
$35.671
+36.27% above average
200-day average
$23.3534
+108.15% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
964.7M USD
P/E (TTM)
22.59×
P/B (TTM)
5.88×
P/S (TTM)
5.49×
EV / EBITDA
-207.24×
Earnings yield
-2.13%
Free cash flow yield
3.60%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
70.58%
Operating margin
-0.92%
Net margin
24.23%
Return on equity
-7.05%
Return on assets
-5.17%
Return on invested capital
-7.60%

Financial health

Debt / equity
0.05×
Current ratio
2.86×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%26%-31%-87%Gross margin, FY2021: 67.14%Gross margin, FY2022: 65.13%Gross margin, FY2023: 63.61%Gross margin, FY2024: 67.16%Gross margin, FY2025: 67.55%Operating margin, FY2021: -10.03%Operating margin, FY2022: -24.00%Operating margin, FY2023: -72.55%Operating margin, FY2024: 12.21%Operating margin, FY2025: -6.60%Net margin, FY2021: -10.34%Net margin, FY2022: -23.81%Net margin, FY2023: -67.88%Net margin, FY2024: 15.74%Net margin, FY2025: -5.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 67.14%. Gross margin FY2022 65.13%. Gross margin FY2023 63.61%. Gross margin FY2024 67.16%. Gross margin FY2025 67.55%. Operating margin FY2021 -10.03%. Operating margin FY2022 -24.00%. Operating margin FY2023 -72.55%. Operating margin FY2024 12.21%. Operating margin FY2025 -6.60%. Net margin FY2021 -10.34%. Net margin FY2022 -23.81%. Net margin FY2023 -67.88%. Net margin FY2024 15.74%. Net margin FY2025 -5.62%.

Income trends

Revenue

379.81M USD+13.79%

Operating income

−25.07M USD−65.84M USD

Net income

−21.35M USD−73.9M USD
Income trends across reported periods438.12M USD204.85M USD−28.41M USD−261.68M USDRevenue, FY2021: 296.4M USDRevenue, FY2022: 321.79M USDRevenue, FY2023: 280.32M USDRevenue, FY2024: 333.79M USDRevenue, FY2025: 379.81M USDOperating income, FY2021: −29.73M USDOperating income, FY2022: −77.23M USDOperating income, FY2023: −203.36M USDOperating income, FY2024: 40.77M USDOperating income, FY2025: −25.07M USDNet income, FY2021: −30.66M USDNet income, FY2022: −76.61M USDNet income, FY2023: −190.28M USDNet income, FY2024: 52.55M USDNet income, FY2025: −21.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 296.4M USD. Revenue FY2022 321.79M USD. Revenue FY2023 280.32M USD. Revenue FY2024 333.79M USD. Revenue FY2025 379.81M USD. Operating income FY2021 −29.73M USD. Operating income FY2022 −77.23M USD. Operating income FY2023 −203.36M USD. Operating income FY2024 40.77M USD. Operating income FY2025 −25.07M USD. Net income FY2021 −30.66M USD. Net income FY2022 −76.61M USD. Net income FY2023 −190.28M USD. Net income FY2024 52.55M USD. Net income FY2025 −21.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue379.81M USD333.79M USD280.32M USD321.79M USD296.4M USD
Cost of goods sold123.24M USD109.63M USD102M USD112.21M USD97.39M USD
Gross profit256.57M USD224.16M USD178.33M USD209.58M USD199.01M USD
Research and development71.43M USD72.41M USD81.87M USD90.39M USD76.53M USD
Selling, general, and administrative210.21M USD205.5M USD201.2M USD196.42M USD152.21M USD
Operating expenses281.64M USD183.39M USD381.69M USD286.81M USD228.73M USD
Interest income9.17M USD11.77M USD11.87M USD3.76M USD160K USD
Depreciation and amortization20.42M USD19.76M USD19.82M USD16.01M USD11.89M USD
Operating income−25.07M USD40.77M USD−203.36M USD−77.23M USD−29.73M USD
Net income−21.35M USD52.55M USD−190.28M USD−76.61M USD−30.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+151.88%
11 comparable reports
Latest EPS result
0.37
Estimate 0.23 · Beat by 59.41%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.420.19-0.03-0.25Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 0.18, estimate 0.05, surprise +260.00%, Beat. Q2 2025, reported Apr 30, 2025: actual -0.19, estimate -0.207, surprise +8.07%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.16, estimate -0.096, surprise -66.03%, Miss. Q4 2025, reported Nov 4, 2025: actual 0.032, estimate -0.082, surprise +138.94%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.12, estimate 0.02, surprise +503.02%, Beat. Q2 2026, reported Apr 28, 2026: actual 0.34, estimate 0.11, surprise +209.09%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.37, estimate 0.232, surprise +59.41%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.24, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates137.23M117.76M98.29M78.83MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 86.58M USD, estimate 84.11M USD, surprise +2.94%, Beat. Q2 2025, reported Apr 30, 2025: actual 84.69M USD, estimate 84.35M USD, surprise +0.40%, Beat. Q3 2025, reported Aug 6, 2025: actual 86.68M USD, estimate 90.57M USD, surprise -4.30%, Miss. Q4 2025, reported Nov 4, 2025: actual 100.06M USD, estimate 95.38M USD, surprise +4.91%, Beat. Q1 2026, reported Feb 24, 2026: actual 108.39M USD, estimate 103.27M USD, surprise +4.95%, Beat. Q2 2026, reported Apr 28, 2026: actual 117.7M USD, estimate 102.03M USD, surprise +15.36%, Beat. Q3 2026, reported Jul 30, 2026: actual 131.95M USD, estimate 114.05M USD, surprise +15.69%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 121.9M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$56.67

16.58% upside
Past 12 months12-month forecastHigh $64.00Average $56.67Low $46.00

Rating distribution

13 ratings
Strong buy00%
Buy1077%
Hold323%
Sell00%
Strong sell00%

Recent analyst actions

7 institutions
Raymond JamesdowngradeOutperformMarket Perform

CDNA news

CDNA peers

ETFs holding CDNA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CDNA

research.disclaimer